Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.36 |
| ▸ | STAT3 | P40763 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064438 | 0.81 | OXTR (0.41) | PPARGSCN9ASCN10ACHRNA7KDM4E | |
| SCHEMBL3057626 | 0.79 | KDM4E (0.43) | PPARGSCN9ACHRNA7KDM4EP2RX3 | |
| SCHEMBL3063119 | 0.76 | GAA (0.58) | NPC1KDM4ERAB9ASTAT3 | |
| SCHEMBL3061602 | 0.75 | RAB9A (0.50) | CHRNA7NPC1RAB9ASTAT3 | |
| SCHEMBL3062332 | 0.74 | KCNQ3 (0.48) | CHRNA7NPC1KDM4ERAB9A | |
| SCHEMBL3654643 | 0.74 | HRH3 (0.38) | PPARGSCN9ACHRNA7P2RX3GFER | |
| SCHEMBL3063818 | 0.74 | MAPT (0.41) | PPARGSCN9ACHRNA7KDM4EP2RX3 | |
| SCHEMBL3705800 | 0.72 | CHRNA7 (0.45) | PPARGCHRNA7RAB9AP2RX3GFER | |
| SCHEMBL3057343 | 0.72 | L3MBTL1 (0.45) | PPARGCHRNA7KDM4EP2RX3 | |
| SCHEMBL3055933 | 0.71 | HRH3 (0.43) | STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | PPARG 1152/4885SCN9A 2616/4885SCN10A 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.